Cargando…

Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research

Dry eye disease (DED) is an emerging health issue affecting people worldwide. There have been rapid advances in the development of novel molecules and targeted therapies for the treatment of DED in the recent past. For testing and optimizing these therapies, it is necessary to have reliable experime...

Descripción completa

Detalles Bibliográficos
Autores principales: Thacker, Minal, Sahoo, Abhishek, Reddy, A Aniruth, Bokara, Kiran K, Singh, Swati, Basu, Sayan, Singh, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276752/
https://www.ncbi.nlm.nih.gov/pubmed/37026256
http://dx.doi.org/10.4103/IJO.IJO_2791_22
_version_ 1785060144539762688
author Thacker, Minal
Sahoo, Abhishek
Reddy, A Aniruth
Bokara, Kiran K
Singh, Swati
Basu, Sayan
Singh, Vivek
author_facet Thacker, Minal
Sahoo, Abhishek
Reddy, A Aniruth
Bokara, Kiran K
Singh, Swati
Basu, Sayan
Singh, Vivek
author_sort Thacker, Minal
collection PubMed
description Dry eye disease (DED) is an emerging health issue affecting people worldwide. There have been rapid advances in the development of novel molecules and targeted therapies for the treatment of DED in the recent past. For testing and optimizing these therapies, it is necessary to have reliable experimental animal models of DED. One such approach is the use of benzalkonium chloride (BAC). Several BAC-induced DED models of rabbits and mice have been described in literature. BAC induces high levels of proinflammatory cytokines in the cornea and conjunctiva, along with epithelial cell apoptosis and reduction of mucins, which leads to tear film instability, thereby successfully simulating human DED. The stability of these models directs whether the treatment is to be applied while BAC is being instilled or after its cessation. In this review, we summarize the previously described BAC animal models of DED and present original data on rabbit DED models created using 0.1%, 0.15%, and 0.2% BAC administration twice daily for two consecutive weeks. The 0.2% BAC model sustained DED signs for 3 weeks, while 0.1% and 0.15% models sustained DED signs for 1–2 weeks after BAC discontinuation. Overall, these models look promising and continue to be used in various studies to investigate the efficacy of therapeutic drugs for DED treatment.
format Online
Article
Text
id pubmed-10276752
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-102767522023-06-18 Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research Thacker, Minal Sahoo, Abhishek Reddy, A Aniruth Bokara, Kiran K Singh, Swati Basu, Sayan Singh, Vivek Indian J Ophthalmol Review Article - Basic Sciences and Applied Research Dry eye disease (DED) is an emerging health issue affecting people worldwide. There have been rapid advances in the development of novel molecules and targeted therapies for the treatment of DED in the recent past. For testing and optimizing these therapies, it is necessary to have reliable experimental animal models of DED. One such approach is the use of benzalkonium chloride (BAC). Several BAC-induced DED models of rabbits and mice have been described in literature. BAC induces high levels of proinflammatory cytokines in the cornea and conjunctiva, along with epithelial cell apoptosis and reduction of mucins, which leads to tear film instability, thereby successfully simulating human DED. The stability of these models directs whether the treatment is to be applied while BAC is being instilled or after its cessation. In this review, we summarize the previously described BAC animal models of DED and present original data on rabbit DED models created using 0.1%, 0.15%, and 0.2% BAC administration twice daily for two consecutive weeks. The 0.2% BAC model sustained DED signs for 3 weeks, while 0.1% and 0.15% models sustained DED signs for 1–2 weeks after BAC discontinuation. Overall, these models look promising and continue to be used in various studies to investigate the efficacy of therapeutic drugs for DED treatment. Wolters Kluwer - Medknow 2023-04 2023-04-05 /pmc/articles/PMC10276752/ /pubmed/37026256 http://dx.doi.org/10.4103/IJO.IJO_2791_22 Text en Copyright: © 2023 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article - Basic Sciences and Applied Research
Thacker, Minal
Sahoo, Abhishek
Reddy, A Aniruth
Bokara, Kiran K
Singh, Swati
Basu, Sayan
Singh, Vivek
Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research
title Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research
title_full Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research
title_fullStr Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research
title_full_unstemmed Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research
title_short Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research
title_sort benzalkonium chloride-induced dry eye disease animal models: current understanding and potential for translational research
topic Review Article - Basic Sciences and Applied Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276752/
https://www.ncbi.nlm.nih.gov/pubmed/37026256
http://dx.doi.org/10.4103/IJO.IJO_2791_22
work_keys_str_mv AT thackerminal benzalkoniumchlorideinduceddryeyediseaseanimalmodelscurrentunderstandingandpotentialfortranslationalresearch
AT sahooabhishek benzalkoniumchlorideinduceddryeyediseaseanimalmodelscurrentunderstandingandpotentialfortranslationalresearch
AT reddyaaniruth benzalkoniumchlorideinduceddryeyediseaseanimalmodelscurrentunderstandingandpotentialfortranslationalresearch
AT bokarakirank benzalkoniumchlorideinduceddryeyediseaseanimalmodelscurrentunderstandingandpotentialfortranslationalresearch
AT singhswati benzalkoniumchlorideinduceddryeyediseaseanimalmodelscurrentunderstandingandpotentialfortranslationalresearch
AT basusayan benzalkoniumchlorideinduceddryeyediseaseanimalmodelscurrentunderstandingandpotentialfortranslationalresearch
AT singhvivek benzalkoniumchlorideinduceddryeyediseaseanimalmodelscurrentunderstandingandpotentialfortranslationalresearch